Akebia Therapeutics, Inc. (AKBA) NASDAQ

0.93

-0.08699997(-8.53%)

Updated at June 02 02:29PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
John Butler	Chief Executive Officer, President & Director	1.46M	1964
Nicholas Grund	Senior Vice President & Chief Commercial Officer	728,914	1970
Erik John Ostrowski	Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer	792,870	1972
Steven Keith Burke	Senior Vice President and Chief Research & Development Officer	860,324	1961
Carolyn Rucci	Senior Vice President, Chief Legal Officer & Secretary	933,304	1981
Richard C. Malabre	Senior VP & Chief Accounting Officer	0	1961
Meredith Bowman	Senior Vice President & Chief People Officer	0	N/A
Justin McCue	Senior VP & Chief Technology Officer	0	N/A
Mercedes Carrasco	Senior Director of Investor & Corporate Communications	0	N/A

Name

Title

Pay

Year Born

John Butler

Chief Executive Officer, President & Director

1.46M

1964

Nicholas Grund

Senior Vice President & Chief Commercial Officer

728,914

1970

Erik John Ostrowski

Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer

792,870

1972

Steven Keith Burke

Senior Vice President and Chief Research & Development Officer

860,324

1961

Carolyn Rucci

Senior Vice President, Chief Legal Officer & Secretary

933,304

1981

Richard C. Malabre

Senior VP & Chief Accounting Officer

1961

Meredith Bowman

Senior Vice President & Chief People Officer

N/A

Justin McCue

Senior VP & Chief Technology Officer

N/A

Mercedes Carrasco

Senior Director of Investor & Corporate Communications

N/A

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.